## Supplemental data

## Inhibition of c-Src Tyrosine Kinase Prevents Angiotensin II-Mediated Connexin43 Remodeling and Sudden Cardiac Death

Ali A. Sovari, MD<sup>1</sup>; Shahriar Iravanian, MD<sup>2</sup>; Elena Dolmatova, MD<sup>3</sup>; Zhe Jiao, MD, PhD<sup>2</sup>; Hong Liu MD, PhD<sup>1</sup>; Shadi Zandieh, MD<sup>1</sup>; Vibhash Kumar, MD<sup>1</sup>; Kun Wang, MD<sup>1</sup>; Kenneth E. Bernstein, MD<sup>4</sup>; Marcelo G. Bonini, PhD<sup>1</sup>; Heather Duffy, PhD<sup>3</sup>; Samuel C. Dudley, MD, PhD, FACC<sup>1</sup>




Figure 1 (supplement). Western blot shows that treatment with Angiotensin II (AngII) type 1 receptor blocker, Losartan (500mg/L in drinking water x 6 weeks) reduces the level of the phospho (Tyr416)-Src protein to 60% compared to untreated ACE8/8 mice supporting that the observed change in the phospho (Tyr416) Src is because of the elevated AngII level via its effect on AngII type 1 receptor.